Matthew joined Oxford Biotherapeutics in 2022 as a program manager. He is dedicated primarily to external innovation, coordinating and delivering target validation data for partnership programs, and business development, developing content and strategies for future partnerships. He currently oversees the ADC development pipeline of the 10 partnered programs in collaboration with Immunogen. He has a Master of Science from UC Berkeley and brings years of experience in early-stage biotech startups. He is passionate about maximizing the quantity and quality of science produced every day.